| First Author | Dionisio-Santos DA | Year | 2020 |
| Journal | Front Neurosci | Volume | 14 |
| Pages | 441 | PubMed ID | 32528242 |
| Mgi Jnum | J:311334 | Mgi Id | MGI:6729424 |
| Doi | 10.3389/fnins.2020.00441 | Citation | Dionisio-Santos DA, et al. (2020) Evaluating the Effect of Interleukin-4 in the 3xTg Mouse Model of Alzheimer's Disease. Front Neurosci 14:441 |
| abstractText | Chronic neuroinflammation has long been hypothesized to be involved in Alzheimer's Disease (AD) progression. Previous research suggests that both anti-inflammatory and inflammatory microglia ameliorate amyloid pathology, but the latter worsen tau pathology. In this study, we sought to determine whether induction of arginase-1 positive microglia with the anti-inflammatory cytokine IL-4 modulates pathology in the 3xTg mouse model of AD. Our findings indicate that a single intracranial IL-4 injection positively modulated performance of 3xTg AD mice in a Novel Object Recognition task, and locally increased the levels of arginase-1 positive myeloid cells when assessed one-week post injection. Furthermore, immunohistochemical analysis revealed decreased tau phosphorylation in IL-4 injected animals; however, we were not able to detect significant changes in tau phosphorylation utilizing Western blot. Lastly, IL-4 injection did not appear to cause significant changes in amyloid beta load. In conclusion, acute intracranial IL-4 led to some positive benefits in the 3xTg mouse model of AD. Although more work remains, these results support therapeutic strategies aimed at modifying microglial activation states in neurodegenerative diseases. |
